At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 20 target
Drug / intervention
Busulfan (BU) +2 moredrug
Likely dose
Busulfan (BU) 3.2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Primary Central Nervous System Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation
In Brief
A Phase 3 clinical trial evaluating Busulfan (BU), Cyclophosphamide (CY), and 1 other intervention for Primary Central Nervous System Lymphoma and 2 related conditions. Targeting 20 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of BUCYE conditioning regimens in primary central nervous system lymphoma undergoing autologous hematopoietic stem cell transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Central Nervous System Lymphoma, Autologous Hematopoietic Stem Cell Transplantation, Conditioning
CountriesChina
Timeline
Phase 3UnknownOverdue
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedNov 2018
Primary CompletionOct 2021
TodayJul 2026
First PostedNov 7, 2018
Enrollment StartNov 1, 2018
Primary CompletionOct 1, 2021
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 7.6 years ago
Interventions
Busulfan (BU)drug
Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
Cyclophosphamide (CY)drug
Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Etoposide (VP-16)drug
Etoposide was administered at 15 mg/kg/day on days -3 to -2.